NCT00998270

Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation Compare With Allogeneic Bone Marrow Transplantation in Multiple Myeloma

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 185 (estimated)
• Sponsor: Tehran University of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

A prospective, randomized trial of autologous bone marrow transplantation compared with allogeneic bone marrow transplantation in multiple myeloma.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
PROCEDURE	Autologous bone marrow transplantation	Autologous transplantation: * Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day * G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days * Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days
PROCEDURE	Allogeneic bone marrow transplantation	Allogeneic * Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days * Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days

Timeline

• Start date: 2009-10-01
• Primary completion: 2014-10-01
• Completion: 2017-10-01
• First posted: 2009-10-20
• Last updated: 2012-06-04

Locations

1 site across 1 country: Iran